LPL and hyperinsulinemic hypoglycemia, familial, 4: In 2012, Glybera®, an AAV vector designed to treat lipoprotein lipase deficiency through expressing lipoprotein lipase in muscle, was approved as the first gene therapy product in the European Union [88].